The Feminist Majority Foundation—they were heroic. They collected over 700,000 petitions from people across the United States ...

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

Cytokinetics , Inc. (NASDAQ:CYTK), with a market capitalization of $5.65 billion, is approaching a pivotal moment in its journey to become a leading player in the cardiovascular therapeutics market.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to read my analysis of DCTH stock.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...

However, Spravato remains restricted under the FDA's REMS program due to its abuse potential. Investors will watch how this regulatory win impacts Johnson & Johnson's pharma segment ahead of earnings.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Given its potential for abuse and misuse, Spravato will be only available through the FDA's Risk Evaluation and Mitigation Strategy (REMS) Program.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...